Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation
Background Hereditary transthyretin amyloidosis (ATTR) is an autosomal dominant disease characterized by amyloid fibril deposition. The TTR c.148G > T mutation (V30L) in ATTR is rarely reported, and its biochemical properties are unknown. Methods Seven patients and two asymptomatic carriers from two unrelated families diagnosed with V30L variant of ATTR were included. Data on clinical manifestations, laboratory examination, electrophysiology, ophthalmological corneal confocal microscopy (CCM), pathology and molecular biological experiments was collected and analyzed. Results Most patients initially experienced paresthesia, with varying degrees of peripheral neuropathy, autonomic dysfunction, and cardiac involvement. Nerve conduction studies showed extensive motor and sensory nerve involvement in upper and lower limbs. CCM revealed reduced corneal nerve density and fiber length. Sural nerve biopsies indicated loss of myelinated nerve fibers, with neurogenic patterns in gastrocnemius muscle biopsies. Asymptomatic carriers had nearly normal electrophysiology but mild reductions in corneal nerve fiber density and length. Sural nerve biopsies in carriers showed mild reductions in small myelinated nerve fibers. V30L mutation impaired thermodynamic and kinetic stability of the mutant protein. Plasma TTR tetramer concentration was lower in ATTR V30L patients compared to healthy donors. Small molecule stabilizers failed to exhibit satisfactory inhibition on fibril formation of V30L mutation in vitro. Conclusion This study highlights the multisystem involvement in ATTR V30L patients, including neuropathy and cardiac issues. Both patients and carriers showed abnormalities in nerve conduction, corneal microscopy, and pathology. The V30L mutation impaired protein stability and reduced plasma TTR tetramer levels. Small molecule stabilizers were ineffective, indicating a need for alternative treatments.
基金:
National Natural Science Foundation of China (82101469, 22222410, 22374148), Dalian Science Foundation for Distinguished Young Scholars (2022RJ04),National High Level Hospital Clinical Research Funding (Interdepartmental Research Project of Peking University First Hospital)(2024IR12, 22cz020301-4802068 ).
第一作者机构:[1]Peking Univ First Hosp, Dept Neurol, 8 Xishiku St, Beijing 100034, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Peking Univ First Hosp, Dept Neurol, 8 Xishiku St, Beijing 100034, Peoples R China[4]Beijing Key Lab Neurovasc Dis Discovery, Beijing 100034, Peoples R China
推荐引用方式(GB/T 7714):
Jiao Hao,Wang Mengdie,Du Kang,et al.Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation[J].NEUROLOGICAL SCIENCES.2024,doi:10.1007/s10072-024-07765-5.
APA:
Jiao, Hao,Wang, Mengdie,Du, Kang,Sun, Jialu,Chu, Xujun...&Meng, Lingchao.(2024).Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation.NEUROLOGICAL SCIENCES,,
MLA:
Jiao, Hao,et al."Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation".NEUROLOGICAL SCIENCES .(2024)